Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Gadolinium Contrast Agents and Brain Safety: Signal vs Noise

Published: Mon, 26 Jun 2017 09:15:47 EDT
Gadolinium deposits in brain tissue of patients who had multiple gadolinium-enhanced MRIs prompted an FDA review, which concluded that no restrictions were necessary. Practitioners remain cautious.
Medscape Radiology

When Drugs and Surgery Don't Work, an Option in Epilepsy

Published: Mon, 26 Jun 2017 09:15:15 EDT
Dr Wilner and epileptologist Dr Jobst discuss two recent studies reporting favorable results of neurostimulation in patients with intractable epilepsy.
Medscape Neurology

Microbiome Profiling: Big Business, but What About the Data?

Published: Mon, 26 Jun 2017 09:14:54 EDT
Personalized microbiome testing kits are more and more common. Does the science back up their usefulness?
Medscape Gastroenterology

CDC Contraception Guidelines: The Latest Updates

Published: Mon, 26 Jun 2017 09:11:40 EDT
Here are the hot-off-the-press revisions to CDC contraception guidelines and recommendations.
CDC Expert Commentary
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Bluebird Bio rebuilds case for blood disorder gene therapy

Published: Fri, 23 Jun 2017 13:46:18 +0000
Bluebird Bio reported encouraging data on its revamped gene therapy for sickle cell disease and beta thalassemia this morning, but shares slipped 6% premarket on some unresolved issues.

Aveo soars as long-beleaguered cancer drug nears approval

Published: Fri, 23 Jun 2017 12:45:58 +0000
Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe. Drug assessors in the region gave the thumbs-up to the tyrosine kinase inhibitor in kidney cancer, sending Aveo’s stock on a tear and teeing up its partner to bring the drug to market.

Novartis-backed GenSight gets cash for gene therapy launch

Published: Fri, 23 Jun 2017 09:12:53 +0000
GenSight Biologics has raised €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and gear up for anticipated approvals on both sides of the Atlantic.

EuroBiotech: More Articles of Note

Published: Thu, 22 Jun 2017 13:14:34 +0000
In our EuroBiotech roundup this week, Galapagos delays cystic fibrosis program, Zealand heads to phase 3 and Pluristem loses out on $30 million. 
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy